Cytonics Corp

01/04/2023

Cytonics is engineering the first "off the shelf" treatment for a $180B Marketplace, jump on our equity crowdfund raise today - https://invest.cytonics.co/tiers.php

01/04/2023

Cytonics Corporation and Sygenx, Inc. have signed a Letter of Intent to assign Sygenx an exclusive license to manufacture and sell the APIC system in the international and domestic markets. Sygenx’s distribution arm, Catalyst Sales & Marketing, was recently acquired by CareStream America, a Canadian-based international distributor of medical devices with a sales force of over 50 domestic sales reps. CareStream America has operational and regulatory expertise in many foreign jurisdictions, including Canada, the EU, and South East Asia. Sygenx has also expressed interest in acquiring a license to sell the APIC system in the veterinary market, and is currently establishing a veterinary distribution company, backed by prominent equine orthopedic physicians, that will target horse breeders and trainers. The successful negotiation of these licensing deals will place APIC in both the human and veterinary markets (both domestically and abroad) which will result in substantial increase Cytonics’ revenues.
The terms of the deal are as follows:
o $900,000 will be paid to Cytonics over the next 2 years as a license acquisition cost
o Cytonics will receive 10% of gross sales of APIC in the human market
o Cytonics will receive 2-5% of gross sales of APIC in the veterinary market
o Cytonics will be guaranteed quarterly minimum payments

01/04/2023

We are proud to announce that our Campaign is has raised over $2,976,276
Don't miss your opportunity to participate in the development of the cure for osteoarthritis! and good ROI

Investment Instructions:
1) Go to: https://invest.cytonics.co/tiers.php
2) Sign up and Place your investment using the online form (you will need a crypto or your bank account # and routing # for ACH transfer or Wire transfer); and
3) After your investment has been initiated there may be a follow-up section to verify your identity for compliance purposes

Cytonics is developing diagnostics and therapeutic medicine for osteoarthritis. Disrupting a $240B industry by pioneering the future of regenerative medicine.

01/04/2023

Cytonics Corporation is poised to make a significant impact on the world of PRP and autologous therapies. The company has conducted extensive research on cartilage degeneration and has developed a unique approach for inhibiting all known causes of cartilage degradation, which they have proven with extensive in vivo and in vitro studies. The beauty of Cytonics’ development is that they are using the body’s own defense mechanism to stop pain and prevent cartilage degeneration. I believe Cytonics Corporation will produce a Quantum leap in Regenerative Medicine”

01/04/2023

We’re excited to share that Cytonics is gearing up to offer company shares to not only accredited investors, but also anybody interested in investing in a growing and proven medical technology company. Learn more on our website.

Cytonics is developing diagnostics and therapeutic medicine for osteoarthritis. Disrupting a $240B industry by pioneering the future of regenerative medicine.

03/25/2012

Back pain is one of the most common conditions that lead Americans to seek help from their doctor. Often, it’s difficult to pinpoint the cause and even harder to treat. For those with chronic back pain, there’s new hope! Read the below article.
*M

01/17/2012

joints produce catabolic proteases, which are chemicals that break down cartilage. This process is what causes musculoskeletal pain. Surgery is an invasive and a last resort (ex. fusion or joint replacement) for pain management in these cases. *M injections is the answer for people who want to manage their pain without surgery. Learn more below.

01/09/2012

US Medical Expenses exceed $185.5 billion dollars spent annually on treating conditions associated with Osteoarthritis, including knee pain, back pain, post traumatic OA, and many other joint conditions

01/05/2012

Cytonics has invested over $500K in patent development, and has filed numerous domestic and international patent applications for its diagnostic and therapeutic technologies. We have obtained U.S. Patent #7,709,215 and #8,338,572 for diagnostics and have a number of other U.S. and foreign patent applications pending